NCT04343651View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

July 21, 2020

Study Completion Date

September 20, 2021

Conditions
Coronavirus Disease 2019
Interventions
DRUG

Placebo

Placebo

DRUG

Leronlimab (700mg)

Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

Trial Locations (12)

10467

Montefiore Medical Center, The Bronx

10601

White Plains Hospital, White Plains

27103

Novant Health, Charlotte

30501

Center for Advanced Research & Education (CARE), Gainesville

43215

Ohio Health, Columbus

90095

University of California, Los Angeles, Los Angeles

92270

Eisenhower Health, Rancho Mirage

97239

Oregon Health and Science University, Portland

92262-4871

Palmtree Clinical Research, Inc., Palm Springs

06510

Yale, New Haven

02215

Beth Israel Deaconess Medical Center, Boston

07962-1905

Atlantic Health System Hospital, Morristown

Sponsors

Lead Sponsor

CytoDyn, Inc.
All Listed Sponsors
lead

CytoDyn, Inc.

INDUSTRY

NCT04343651 - Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | Biotech Hunter | Biotech Hunter